Leelyn Smith, LLC Vertex Pharmaceuticals Inc Transaction History

Leelyn Smith, LLC

$516 Million
Q2 2024

A detailed history of Leelyn Smith, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Leelyn Smith, LLC holds 478 shares of VRTX stock, worth $240,171. This represents 0.04% of its overall portfolio holdings.

Number of Shares

478

Previous 491 2.65%

Holding current value

$240,171

Previous $205,000 9.27%

% of portfolio

0.04%

Previous 0.04%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	SELL	$392.81 - $485.53 $5,106 - $6,311	-13 Reduced 2.65%	478 $224,000
Q1 2024 May 13, 2024	BUY	$407.69 - $446.08 $200,175 - $219,025	491 New	491 $205,000
Q2 2023 Aug 10, 2023	SELL	$314.42 - $351.91 $54,080 - $60,528	-172 Reduced 16.78%	853 $300,000
Q1 2023 May 12, 2023	SELL	$283.23 - $323.1 $237,913 - $271,404	-840 Reduced 45.04%	1,025 $322,000
Q4 2022 Feb 10, 2023	BUY	$285.76 - $321.48 $299,762 - $337,232	1,049 Added 128.55%	1,865 $538,000
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $500,013 - $557,897	-1,826 Reduced 69.11%	816 $236,000
Q2 2022 Aug 09, 2022	SELL	$234.96 - $292.55 $529,599 - $659,407	-2,254 Reduced 46.04%	2,642 $744,000
Q1 2022 May 11, 2022	BUY	$221.42 - $260.97 $32,327 - $38,101	146 Added 3.07%	4,896 $1.28 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $97,532 - $123,120	551 Added 13.12%	4,750 $1.04 Million
Q3 2021 Nov 12, 2021	BUY	$181.39 - $202.99 $12,515 - $14,006	69 Added 1.67%	4,199 $762,000
Q2 2021 Aug 31, 2021	SELL	$187.49 - $221.1 $110,056 - $129,785	-587 Reduced 12.44%	4,130 $833,000
Q1 2021 May 05, 2021	BUY	$207.02 - $241.31 $976,513 - $1.14 Million	4,717 New	4,717 $1.01 Million

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Leelyn Smith, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Leelyn Smith, LLC with notifications on news.

Account